Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26836961 | 0.78 | ALOX5 (0.58) | ALOX5PTGS1PTGS2SLC6A4GAA | |
| SCHEMBL8756918 | 0.75 | ALOX5 (0.54) | ALOX5PTGS1PTGS2SLC6A4GAA | |
| SCHEMBL26675964 | 0.72 | CYP3A4 (0.55) | ACHE | |
| SCHEMBL29736086 | 0.72 | CYP3A4 (0.55) | ACHE | |
| SCHEMBL8757766 | 0.72 | ALOX5 (0.50) | ALOX5PTGS1PTGS2SLC6A4BCHE | |
| SCHEMBL26836994 | 0.72 | DRD1 (0.56) | SLC6A4DRD2DRD1DRD5DRD3 | |
| SCHEMBL8756914 | 0.72 | ALOX5 (0.50) | ALOX5PTGS1PTGS2SLC6A4BCHE | |
| SCHEMBL7657617 | 0.71 | ALOX5 (0.56) | ALOX5PTGS1PTGS2SLC6A4BCHE | |
| Hydrochloric Acid SCHEMBL8758460 | 0.71 | ALOX5 (0.49) | ALOX5PTGS1PTGS2SLC6A4BCHE | |
| SCHEMBL26838578 | 0.70 | CYP3A4 (0.52) | ALOX5PTGS1PTGS2DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRIA4, GRIA3, GRIN3A | ALOX5 3288/4885PTGS1 3765/4885PTGS2 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.